Even as it’s moving into the US tobacco alternatives market, Philip Morris International (PMI) may be setting itself up for a future move into the cannabis industry. The company has reportedly purchased a patent for a genetically modified cannabis plant, and is said to have invested $20m in an Israeli company that makes cannabis inhalers.
Meanwhile, an expert on cannabis and behaviour has told CBD-Intel that reports of 60 people suffering medical ill-effects from vaping products marketed as containing cannabinoid oil suggested symptoms consistent with them having received “tainted product”.
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
Do the Novel Food regulations in Europe affect your business?
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.